Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials
- Pages: 52
- Published: August 2020
- Report Code: GDHCHT167
This 52-page PowerPoint based report gives an important expert analysis on how COVID-19 is impacting clinical trials and the potential move toward decentralized clinical trials. Findings are based on a survey conducted with 150 respondents from around the world that belonged to Pharma/Biotech, Government/Academic Institutions, CROs, CMOs, or other contract service providers. The report includes:
Background, Objectives and Designs.
Primary Concerns, which include business concerns, clinical trial concerns for decentralized clinical trials and addressing trial disruption.
Movement Toward Decentralized Trials, including pre and post pandemic decentralized clinical trials use, future movement toward using decentralized clinical trials and cost comparison.
Challenges Facing Decentralized Trials, which explores the biggest challenges and changes that are anticipated for decentralized clinical trials.
A total of 150 GlobalData Pharma clients and prospects from the around the world participated in the seven-minute survey, which was fielded from June 4, 2020 to June 22, 2020.
This report includes and is based around industry opinions on COVID-19’s impact on clinical trials and the use of decentralized clinical trials.
Reasons to buy
Understand companies’ primary concerns about the COVID-19 pandemic.
Determine the impact of COVID-19 to date on clinical trials.
Assess companies’ future plans to use decentralized clinical trials.
Track changes to clinical trial strategy and attitudes.
Table of Contents
Table of Contents (PowerPoint Deck)
1 Study Design
1.2 Objectives and Design
2 Primary Business and Clinical Trial Concerns
2.1 Primary Business Concerns
2.2 Primary Clinical Trial Concerns
2.3 Addressing Clinical Trial Disruptions
3 Movement Toward Decentralized Trials
3.1 Pre-pandemic Decentralized Trials Use
3.2 Post-pandemic Decentralized Trials Use
3.3 Future Movement Toward Decentralized Clinical Trial Use
3.4 Cost Comparison
4 Challenges Facing Decentralized Trials
4.1 Biggest Challenges
4.2 Biggest Changes